New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 21  •  10:47AM ET
225.87
Dollar change
+17.48
Percentage change
8.39
%
IndexS&P 500 P/E47.97 EPS (ttm)4.71 Insider Own8.90% Shs Outstand715.90M Perf Week9.57%
Market Cap161.73B Forward P/E26.57 EPS next Y8.50 Insider Trans-1.95% Shs Float652.32M Perf Month18.59%
Enterprise Value177.34B PEG6.10 EPS next Q2.38 Inst Own81.61% Short Float1.32% Perf Quarter14.14%
Income3.41B P/S6.74 EPS this Y3.96% Inst Trans-0.01% Short Ratio2.01 Perf Half Y17.60%
Sales24.01B P/B3.09 EPS next Y9.31% ROA4.26% Short Interest8.60M Perf YTD-1.60%
Book/sh73.10 P/C54.70 EPS next 5Y7.86% ROE6.68% 52W High274.21 -17.63% Perf Year-16.95%
Cash/sh4.13 P/FCF33.27 EPS past 3/5Y-15.01% 9.03% ROIC4.93% 52W Low171.00 32.09% Perf 3Y0.44%
Dividend Est.1.25 (0.55%) EV/EBITDA23.42 Sales past 3/5Y-6.76% 5.92% Gross Margin61.52% Volatility2.34% 2.76% Perf 5Y12.48%
Dividend TTM1.23 (0.54%) EV/Sales7.39 EPS Y/Y TTM-16.60% Oper. Margin21.59% ATR (14)6.79 Perf 10Y276.96%
Dividend Ex-DateSep 26, 2025 Quick Ratio1.22 Sales Y/Y TTM-3.24% Profit Margin14.21% RSI (14)70.59 Recom1.41
Dividend Gr. 3/5Y8.74% 9.69% Current Ratio1.62 EPS Q/Q-36.83% SMA2010.75% Beta0.80 Target Price243.05
Payout20.42% Debt/Eq0.35 Sales Q/Q3.36% SMA5011.74% Rel Volume4.61 Prev Close208.39
Employees63000 LT Debt/Eq0.32 EarningsOct 21 BMO SMA20010.80% Avg Volume4.28M Price225.87
IPODec 10, 1969 Option/ShortYes / Yes EPS/Sales Surpr.9.80% 0.92% Trades Volume4,689,247 Change8.39%
Date Action Analyst Rating Change Price Target Change
Oct-08-25Downgrade Rothschild & Co Redburn Buy → Neutral $220
Jul-11-25Upgrade Scotiabank Sector Perform → Sector Outperform $275
Apr-10-25Upgrade Barclays Equal Weight → Overweight $205
Mar-21-25Upgrade Goldman Neutral → Buy $260
Mar-14-25Upgrade Stifel Hold → Buy $260
Feb-03-25Downgrade Raymond James Outperform → Mkt Perform
Dec-23-24Initiated Scotiabank Sector Perform
Dec-19-24Initiated Guggenheim Buy $275
Dec-13-24Upgrade BofA Securities Neutral → Buy $290
Oct-31-24Upgrade Wolfe Research Peer Perform → Outperform $285
Today 09:42AM
09:30AM
07:15AM
06:44AM
06:23AM
06:17AM Loading…
06:17AM
06:09AM
06:00AM
Oct-20-25 11:40AM
Oct-19-25 11:04PM
07:33AM
Oct-17-25 10:18AM
Oct-16-25 04:35PM
01:07PM
09:15AM
10:00AM Loading…
Oct-15-25 10:00AM
Oct-14-25 11:04AM
10:00AM
Oct-13-25 05:21AM
12:26AM
Oct-08-25 11:24AM
Oct-06-25 04:00PM
02:45PM
Oct-04-25 05:01PM
Oct-03-25 06:27AM
Oct-02-25 11:40AM
02:55AM
Oct-01-25 05:35PM
04:01PM
Sep-30-25 12:02AM
11:06AM Loading…
Sep-27-25 11:06AM
Sep-23-25 04:15PM
Sep-22-25 09:35AM
08:54AM
Sep-18-25 10:43AM
Sep-16-25 11:01AM
Sep-15-25 09:00AM
Sep-14-25 11:31PM
Sep-11-25 11:52AM
Sep-10-25 08:31AM
Sep-09-25 04:15PM
Sep-08-25 12:33AM
Sep-02-25 11:24AM
Sep-01-25 11:01AM
Aug-28-25 11:30AM
Aug-22-25 07:52AM
Aug-21-25 11:30AM
Aug-18-25 09:30AM
Aug-17-25 02:14AM
Aug-14-25 11:42AM
Aug-13-25 12:43PM
10:11AM
08:41AM
Aug-12-25 10:30PM
08:30AM
04:49AM
Aug-11-25 11:40AM
Aug-08-25 08:43AM
Aug-04-25 09:00AM
Aug-01-25 04:50PM
12:39PM
Jul-31-25 04:15PM
Jul-30-25 07:22AM
05:08AM
04:20AM
03:37AM
Jul-29-25 04:13PM
01:43PM
04:00AM
01:31AM
Jul-28-25 10:45AM
Jul-26-25 07:44PM
Jul-25-25 11:28PM
09:50AM
Jul-24-25 08:35PM
01:38PM
11:40AM
Jul-23-25 09:45AM
06:46AM
03:04AM
Jul-22-25 03:14PM
02:05PM
12:02PM
11:26AM
11:15AM
10:28AM
10:12AM
09:30AM
07:10AM
06:40AM
06:08AM
06:07AM
06:02AM
06:00AM
03:36AM
Jul-21-25 06:02AM
03:27AM
Jul-20-25 11:07PM
01:15PM
Jul-19-25 06:08AM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
List TeriDirectorAug 22 '25Sale211.062,778586,31920,751Aug 25 05:00 PM
List TeriDirectorAug 22 '25Proposed Sale211.062,778586,320Aug 22 12:18 PM
LOHR WALTER GFormer DirectorJul 22 '25Proposed Sale188.152,719511,588Jul 22 11:49 AM
Zerhouni Elias A.DirectorJul 15 '25Option Exercise59.343,928233,08842,014Jul 16 05:01 PM
SCHWIETERS JOHN TDirectorJul 15 '25Option Exercise59.343,928233,08821,024Jul 16 05:01 PM
List TeriDirectorJul 02 '25Option Exercise59.343,928233,08824,667Jul 07 05:00 PM
RALES STEVEN MChairmanMay 12 '25Sale196.741,250,000245,919,3913,105,808May 14 05:19 PM
RALES STEVEN MOfficerMay 12 '25Proposed Sale194.821,250,000243,525,000May 12 09:30 PM
Raskas DanielFormer OfficerMay 02 '25Proposed Sale201.037,0531,417,865May 02 10:45 AM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Option Exercise76.477,801596,54230,984May 01 05:01 PM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Sale198.0015,8053,129,42415,179May 01 05:01 PM
Riley Christopher PaulOfficerApr 30 '25Proposed Sale198.0015,8053,129,421Apr 30 03:41 PM
Glenstone FoundationSee RemarksApr 24 '25Proposed Sale196.50598,281117,562,216Apr 24 05:28 PM
King WilliamFormer OfficerMar 11 '25Proposed Sale207.1464,69713,401,340Mar 11 04:03 PM
King WilliamOfficerFeb 21 '25Proposed Sale209.97114,35124,010,531Feb 21 04:18 PM
Sabeti Pardis Cformer Board of DirectorsFeb 18 '25Proposed Sale204.284,337885,953Feb 18 01:04 PM
SPOON ALAN GDirectorFeb 07 '25Option Exercise59.343,928233,088121,068Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Sale206.46550113,553120,518Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Proposed Sale206.46550113,553Feb 07 03:34 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Option Exercise58.595,700333,96325,930Jan 31 05:00 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Sale224.135,7001,277,54120,230Jan 31 05:00 PM
Ellis Brian WOfficerJan 30 '25Proposed Sale224.135,7001,277,542Jan 30 12:56 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Option Exercise58.5926,3181,541,97241,543Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Sale236.5926,3186,226,49715,225Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 25 '24Sale238.008,3701,992,06015,225Nov 27 05:01 PM
Raskas DanielOfficerNov 26 '24Proposed Sale236.5926,3186,226,496Nov 26 04:40 PM
Raskas DanielOfficerNov 25 '24Proposed Sale238.008,3701,992,060Nov 25 12:04 PM
Glenstone FoundationSee RemarksNov 05 '24Proposed Sale247.76100,00024,776,000Nov 05 04:01 PM
Weidemanis JoakimFormer DirectorOct 23 '24Proposed Sale254.9517,6594,502,216Oct 23 01:10 PM